Shinobi Strengthens Leadership to Propel Scalable Immune-Evasive Cell Therapies to the Clinic

Company appoints Dr. Luis Borges as first Chief Scientific Officer (CSO) and Dr. Steven Katz as first Chief Medical Officer (CMO). Dr. Katy Rezvani and Dr. Georg Schett join Shinobi’s world-class Scientific Advisory Board (SAB), alongside Dr. Carl June. New appointments cap Shinobi’s…